Health Status Impairments in Tyrosine Kinase Inhibitor-Treated Chronic Myeloid Leukemia Patients Compared with Blood or Marrow Transplant Survivors and Non-Cancer Controls: A Clinical Review
Posted inClinical Updates Hematology-Oncology news

Health Status Impairments in Tyrosine Kinase Inhibitor-Treated Chronic Myeloid Leukemia Patients Compared with Blood or Marrow Transplant Survivors and Non-Cancer Controls: A Clinical Review

This review synthesizes evidence on health status impairments in long-term TKI-treated CML survivors relative to BMT survivors and non-cancer controls, emphasizing rates of functional impairment, activity limitation, frailty, and quality of life impacts, highlighting the necessity for vigilant survivorship care.
Histidine-Rich Glycoprotein as a Modulator of Platelet Adhesion and Aggregation: Mechanistic Insights and Clinical Implications
Posted inClinical Updates Hematology-Oncology Internal Medicine news

Histidine-Rich Glycoprotein as a Modulator of Platelet Adhesion and Aggregation: Mechanistic Insights and Clinical Implications

Histidine-rich glycoprotein (HRG) directly modulates platelet adhesion and aggregation by binding platelet receptors GPIbα and GPIIb/IIIa, competing with key ligands VWF and fibrinogen, thus attenuating thrombus formation; reduced HRG in sepsis and COVID-19 correlates with heightened platelet reactivity.
Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap
Posted inClinical Updates Hematology-Oncology news

Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap

This review explores the Global Lymphoma Registry Alliance’s roadmap for leveraging multinational real-world data collaborations to address lymphoma’s heterogeneity, optimize treatment strategies, and improve patient outcomes worldwide through data harmonization, multi-stakeholder collaboration, and innovative registry integration.
Prognostic Impact of IPI Risk Factors on CAR T-Cell Therapy Versus Allogeneic Stem Cell Transplantation in Relapsed/Refractory Large B-Cell Lymphoma
Posted inHematology-Oncology news Oncology

Prognostic Impact of IPI Risk Factors on CAR T-Cell Therapy Versus Allogeneic Stem Cell Transplantation in Relapsed/Refractory Large B-Cell Lymphoma

This study compares outcomes of CAR T-cell therapy and allogeneic stem cell transplantation based on IPI risk factors in relapsed/refractory LBCL, highlighting favorable survival with CAR T-cell therapy in low-risk patients but advocating alloSCT for high-risk cases.